Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3094194 | 0.87 | HRH3 (0.69) | HRH3CYP2D6 | |
| SCHEMBL3094797 | 0.85 | HRH3 (0.64) | HRH3CYP2D6 | |
| SCHEMBL3100392 | 0.84 | HRH3 (0.66) | HRH3CYP2D6 | |
| SCHEMBL3093649 | 0.82 | HRH3 (0.68) | HRH3CYP2D6HRH1 | |
| SCHEMBL3087981 | 0.82 | HRH3 (0.58) | HRH3CYP2D6 | |
| SCHEMBL3094454 | 0.81 | HRH3 (0.74) | HRH3CYP2D6 | |
| SCHEMBL3086369 | 0.80 | HRH3 (0.84) | HRH3CYP2D6 | |
| SCHEMBL3087990 | 0.79 | HRH3 (0.69) | HRH3CYP2D6HRH1 | |
| SCHEMBL3097172 | 0.79 | HRH3 (0.72) | HRH3CYP2D6 | |
| SCHEMBL3089467 | 0.79 | HRH3 (0.72) | HRH3CYP2D6HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207331-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | claimed |
| US-7799773-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2010-09-21 | — | — | US | claimed |
| US-20100145040-A1 | Benzazepine Derivatives For The Treatment of Neurological Disorders | GLAXO GROUP LIMITED | 2010-06-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145040-A1 | Benzazepine Derivatives For The Treatment of Neurological Disorders | GRIN2C, GRIN2A, GRIN2B | HRH3 450/4885CYP2D6 474/4885ALDH1A1 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.